Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...
Often, those expectations are set by the business itself ... Check out Benzinga’s guidance calendar so you know when companies in which you are interested — or have invested — are issuing ...
Altria's Q4 earnings matched expectations, with a $1 billion share buyback authorized and strong sales growth, while projecting modest 2025 EPS growth of 2-5%.
Good day, ladies and gentlemen, and welcome to Northrop Grumman's fourth quarter 2024 conference call. Today's call is being recorded. My name is Josh, and I will be your operator today. [Operator ...